<DOC>
	<DOCNO>NCT00306904</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics , safety preliminary efficacy 3 dos Cand5 . Cand5 small interfering RNA molecule selectively silence mRNA encode VEGF . The target population patient diabetic macular edema .</brief_summary>
	<brief_title>Safety Efficacy Study Small Interfering RNA Molecule ( Cand5 ) Treat Diabetic Macular Edema</brief_title>
	<detailed_description>Diabetic retinopathy lead cause newly diagnose blindness work age ( 20-74 ) population United States1 diabetic macular edema ( DME ) lead cause vision loss diabetic retinopathy . DME result breakdown retinal capillary endothelium patient diabetes mellitus ( Type I II ) . A key factor development DME permeability blood-retinal barrier . The breakdown endothelial tight junction capillary wall retinal vasculature lead increase permeation salt , protein , water capillary luminal side barrier accumulation fluid extracellular space . Multiple agent appear contribute disruption blood-retina barrier , include vasoactive agent , prostaglandin vascular endothelial growth factor ( VEGF ) . VEGF peptide promote neovascularization increase vascular permeability . If result fluid amount remove active pump mechanism ( retinal pigment epithelium ) , fluid continue accumulate edema develops . When thicken evolves threatens center fovea high risk visual loss . Cand5 synthetic double strand RNA ( dsRNA ) oligonucleotide . The molecule duplex form hybridization two partially complementary single strand RNAs 3 ' end cap 2 deoxyribose ( dT ) unit . Hybridization occur across 19 ribose base pair yield Cand5 molecule . Cand5 molecular weight 13,345 grams/mole . Cand5 selectively silence mRNA encode VEGF . A comparison make three ( 3 ) treatment arm regard safety , efficacy , duration effect determine safe efficacious dose Cand5 appropriate evaluation future pivotal trial .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>1 . Patients must male female age 21 old . 2 . Patient must sign ( give ) copy write informed consent form . 3 . Patients must diagnosis diabetes mellitus ( type 1 type 2 ) . Patients follow consider sufficient evidence diabetes present : Current regular use insulin treatment diabetes mellitus OR Current regular use oral antihyperglycemia agent treatment diabetes OR Documented diabetes WHO criteria 4 . Patients must ETDRS best correct visual acuity 69 24 letter ( 20/40 20/320 Snellen Equivalent ) study eye . 5 . Patients must mean retinal thickness OCT â‰¥ 250 micron central subfield . 1 . Patients history chronic renal failure require dialysis kidney transplant . 2 . A condition , opinion investigator , would preclude participation study ( e.g. , unstable medical status include blood pressure glycemic control ) , include : Patients poor glycemic control , within last 4 month , initiate intensive insulin treatment ( pump multiple daily injection ) plan next 4 month enrol . Patients HbA1C &gt; 10 % OR Patients systolic blood pressure great 170 mmHg and/or diastolic blood pressure great 100 mmHg ( Note : If blood pressure bring 170/100 mmHg antihypertensive treatment , patient become eligible ) . 3 . Past panretinal photocoagulation ( PRP ) diabetes within 12 week screen PRP expect need next three month study eye . 4 . Focal laser therapy retina study eye within 12 week screen . 5 . Any intraocular surgery ocular laser procedure study eye within 12 week screen . 6 . Participation investigational trial within 30 day study entry involve treatment drug receive regulatory approval time study entry .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Macular</keyword>
	<keyword>Edema</keyword>
	<keyword>Diabetic</keyword>
	<keyword>Retinopathy</keyword>
</DOC>